AstraZeneca signs a deal worth up to $247M with US-based Absci Corp. to harness Absci’s AI tech for large-scale protein analysis to find a viable cancer therapy (Michael Peel/Financial Times)

AstraZeneca signs a deal worth up to $247M with US-based Absci Corp. to harness Absci’s AI tech for large-scale protein analysis to find a viable cancer therapy (Michael Peel/Financial Times)

Michael Peel / Financial Times:
AstraZeneca signs a deal worth up to $247M with US-based Absci Corp. to harness Absci’s AI tech for large-scale protein analysis to find a viable cancer therapy  —  Deal with Absci is the latest between big pharma and tech companies to build new disease treatments